Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05889793 · ClinicalTrials.gov registry record · Phase 2
Evaluating Emetine for Viral Outbreaks (EVOLVE)
A Phase 2 study, sponsored by Johns Hopkins University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT05889793: Clinical Trial Phase 2 study, sponsored by Johns Hopkins University.
NCT05889793 is a Phase 2 study that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 4 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05889793, a Phase 2 study, was terminated before completion, sponsored by Johns Hopkins University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The goal of this clinical trial (phase 2/phase 3) is to evaluate the efficacy and safety of emetine administered orally for symptomatic Covid-19 patients in patients ages 30 years and above. Participants will be asked to: * Take Emetine 6mg orally for 10 consecutive days * Be monitored by healthcare staff or self-monitor for daily vital signs and symptoms * Undergo blood draws Researchers will compare the control group given placebo medicine to assess if emetine improved the symptoms of Covid-19.
Primary Outcome
Effectiveness of emetine will be assessed by a 1) composite outcome of Hospitalization, ICU admission, mechanical ventilation, death
Interventions
- DRUG Placebo
- DRUG Emetine Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2024-05-15 |
| Est. Completion | 2025-12-15 |
| Phase | Phase 2 |
Why NCT05889793 stopped before completion
NCT05889793 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05889793 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05889793 about?
NCT05889793 is a clinical study titled "Evaluating Emetine for Viral Outbreaks (EVOLVE)". The goal of this clinical trial (phase 2/phase 3) is to evaluate the efficacy and safety of emetine administered orally for symptomatic Covid-19 patients in patients ages 30 years and above. Participants will be asked to: * Take Emetine 6mg orally for 10 consecutive days * Be monitored by healthcar...
What is the current status of trial NCT05889793?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2024-05-15. Estimated completion is 2025-12-15.
What interventions are being tested in trial NCT05889793?
The interventions under investigation include: Placebo (DRUG), Emetine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT05889793?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05889793's enrollment target sits among peer trials
4 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI